Sprint Bioscience AB (publ) (STO:SPRINT)
Sweden · Delayed Price · Currency is SEK 3.520
+0.100 (2.92%)
May 21, 2026, 12:56 PM CET
Sprint Bioscience AB Company Description
Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia.
It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer.
The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes.
Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.
Sprint Bioscience AB (publ)
| Country | Sweden |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Johan Emilsson |
Contact Details
Address: Novum Huddinge, Stockholm County Stockholm County Sweden | |
| Phone | 46 84 11 44 55 |
Stock Details
| Ticker Symbol | SPRINT |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0006343745 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Johan Emilsson | Chief Executive Officer |
| Prof. Pär Nordlund | Founder |
| Dr. Martin Andersson | Co-Founder, Research Director and Chief Scientific Officer |
| Dr. Kenth Hallberg | Founder and Director of Structural Chemistry |
| Jenni Bjornulfson | Chief Financial Officer |
| Anne-Marie Wenthzel | Chief Business Officer |